Advertisement
Advertisement
U.S. markets open in 9 hours 15 minutes
Advertisement
Advertisement
Advertisement
Advertisement

NexImmune, Inc. (NEXI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.6500+0.0150 (+2.36%)
At close: 04:00PM EDT
0.6500 0.00 (0.00%)
After hours: 06:16PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close0.6350
Open0.6528
Bid0.6472 x 800
Ask0.6600 x 3200
Day's Range0.6104 - 0.6550
52 Week Range0.5100 - 15.3400
Volume105,691
Avg. Volume1,722,800
Market Cap15.045M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.5240
Earnings DateNov 10, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NEXI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NexImmune, Inc.
    Daily – Vickers Top Insider Picks for 08/31/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 11:00 am ET. The webcast will be accessible on the Investor

  • Benzinga

    NexImmune Shares Jump On Immunotherapy Pact For Rare Cancers, Autoimmune Disorders

    Selexis SA and NexImmune Inc (NASDAQ: NEXI) have agreed to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients. Per the agreement, NexImmune will leverage Selexis' SUREtechnology Platform, a suite of cell line development technologies significantly reducing the time, effort, and costs associated with developing high-performance mammalian cell lines. Also Read: NexImmune Pauses Developing Multiple Myeloma

  • Business Wire

    Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

    GENEVA & GAITHERSBURG, Md., September 08, 2022--Selexis SA, a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients. Per the agreement, NexImmune will leverage Selexis’ SUREtechnology Platfor

Advertisement
Advertisement